Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally administered, direct-acting, reversibly binding P2Y12 platelet inhibitor. It is indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* **Acute Coronary Syndrome (ACS):** To reduce the rate of thrombotic cardiovascular events in patients with ACS.
* **Myocardial Infarction (MI):** For patients with a history of MI (at least 12 months prior) to reduce the rate of thrombotic cardiovascular events.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* **History of MI (at least 12 months prior):**
* **Maintenance Dose:** 60 mg orally twice daily.
* **Note:** Patients should also receive aspirin 75-100 mg orally once daily, unless otherwise specified by local protocol.
## Pediatric Dosing
Ticagrelor is not recommended for use in pediatric patients due to a lack of data.
## Dose Adjustments
* **Hepatic Impairment:**
* **Mild to moderate:** No dose adjustment recommended.
* **Severe:** Use with caution; data is limited.
* **Renal Impairment:** No dose adjustment recommended.
## Contraindications
* Documented hypersensitivity to ticagrelor or any of its excipients.
* Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).
## Adverse Effects
* **Most Common:** Dyspnea, bleeding (including fatal and life-threatening), bradycardia.
* **Serious:** Major bleeding, ventricular pauses, angioedema.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Strong inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin) can increase ticagrelor exposure and risk of bleeding. Strong inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) can decrease ticagrelor exposure.
* **CYP3A4 Substrates:** Ticagrelor can increase the exposure of CYP3A4 substrates (e.g., simvastatin, atorvastatin).
* **Other Antiplatelets/Anticoagulants:** Concomitant use increases the risk of bleeding.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Assess for dyspnea, which may be transient.
* Consider ECG monitoring for bradycardia in patients with risk factors.
## Clinical Pearls
* Ticagrelor is a reversibly binding P2Y12 inhibitor, meaning its effect can be reversed more quickly than clopidogrel if needed, though the clinical significance of this reversibility is debated.
* The 60 mg dose is typically used for long-term maintenance in patients with a history of MI beyond the initial ACS treatment period.
* Dyspnea is a common side effect and is usually not clinically significant; however, it should be evaluated to rule out other causes.
* Avoid concomitant use of strong CYP3A4 inhibitors and inducers.
* When discontinuing ticagrelor, especially in ACS patients, a significant increase in thrombotic events has been observed. Reassess the need for continued antiplatelet therapy.
***
*Please verify this information with the most current prescribing information and local protocols.*
